Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, has announced its participation in two upcoming healthcare conferences. The company will engage in analyst-led fireside chats at:
- The 2025 RBC Capital Markets Global Healthcare Conference on May 21st at 8:30 AM ET
- The 2025 Jefferies Global Healthcare Conference on June 4th at 8:45 AM ET
Both events will be accessible via live audio webcast through the "Events" page on Pacira's investor website. Recordings will remain available for two weeks after each event.
Pacira BioSciences (NASDAQ: PCRX) announced it will present findings from its Phase 1 study of PCRX-201, a gene therapy candidate for knee osteoarthritis, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on May 15, 2025. The presentation will focus on how neutralizing antibodies (NAbs) affect the therapy's efficacy, safety, and potential for redosing.
Dr. MiJeong Kim, Senior Director of Translational Sciences, will deliver the presentation titled "Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy." Additionally, Pacira will host a symposium on High-Capacity Adenoviral Vectors (HCAd) for common diseases, featuring speakers from Baylor College of Medicine and Pacira's development team.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. markets close.
Key details:
- Conference Call Time: 4:30 p.m. ET
- Participation Options: Live conference call and webcast
- Access Method: Pre-registration required for Q&A telephone participation
- Alternative Access: Live audio webcast available through "Events" page on investor.pacira.com
- Replay Availability: Webcast recording accessible for approximately two weeks post-call
Pacira BioSciences (Nasdaq: PCRX) has announced promising two-year efficacy data for its gene therapy candidate PCRX-201 in treating knee osteoarthritis. The study, presented at the 2025 OARSI World Congress, demonstrated sustained improvements in knee pain, stiffness, and function across all severity levels following a single injection.
The Phase 1 trial involved 72 patients aged 30-80, with two cohorts receiving different treatment protocols. The corticosteroid-pretreated cohort showed superior results with 48-65% pain reduction and 53-72% stiffness reduction, compared to 41-58% pain and 33-53% stiffness reductions in the non-pretreated group.
No serious treatment-related adverse events were reported. The most common side effect was joint swelling, occurring in 36% of pretreated patients versus 61% of non-pretreated patients. PCRX-201 received FDA's RMAT designation in March 2024 and EMA's ATMP designation in May 2023. A Phase 2 study (ASCEND) is currently underway.
Pacira BioSciences (Nasdaq: PCRX) has announced the upcoming presentation of new 104-week efficacy data for their gene therapy candidate PCRX-201 (enekinragene inzadenovec) at the 2025 OARSI World Congress in Incheon, South Korea.
The presentation, titled 'Improvements in Pain, Stiffness, and Function After a Single Intraarticular Injection of Gene Therapy PCRX-201 for Knee Arthritis Osteoarthritis: A Subgroup Analysis by Structural Severity,' will be delivered by Professor Ali Mobasheri from the University of Oulu and State Research Institute Centre for Innovative Medicine.
The data demonstrates results following a single local administration for patients with mild to severe osteoarthritis of the knee. The presentation is scheduled for April 25 and 26, 2025, from 3:30-4:15 PM KST.